Amarin, Lotus Pharmaceuticals partner to commercialize Vazkepa in Southeast Asia

Amarin Corporation (AMRN) and Lotus Pharmaceuticals (LTUS) announced that the two companies have entered into a long-term exclusive partnership to distribute and commercialize VAZKEPA across 10 countries, including nine in Southeast Asia and South Korea. VAZKEPA capsules have been approved and commercialized in a number of global markets, including the U.S. and European markets, as the first prescription treatment comprised solely of the active ingredient, icosapent ethyl, a highly purified form of eicosapentaenoic acid. Under the terms of the agreement, Lotus will have exclusive rights to distribution and commercial promotion for VAZKEPA in South Korea and nine countries in ASEAN: Brunei, Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. As part of the agreement, Amarin will receive an upfront payment as well as pricing and reimbursement and sales milestone payments based on net sales of the product. Amarin will be responsible for supplying finished product to Lotus at a pre-defined supply price.